The pharmaceutical industry has long been viewed through a binary lens. On one side, the high-stakes, high-margin world of patented […]

An investigative analysis of the business architecture behind pharma’s most durable profit model When Pfizer’s patent on atorvastatin expired in

The maturation of algorithmic discovery The pharmaceutical industry reached an inflection point in 2025 as artificial intelligence transitioned from a

The pharmaceutical industry is struggling with its own productivity. The cost of bringing a single new chemical entity to market

1. The Economics of Managed Exclusivity The pharmaceutical industry operates on a unique economic premise: huge upfront investment in research

Executive Summary The pharmaceutical sector currently faces a distinct legal friction where federal health policy conflicts with intellectual property statutes.

Executive Summary The biopharmaceutical and life sciences sectors face a central, defining strategic tension: the optimal allocation of capital between

In the high-stakes world of pharmaceuticals and biotechnology, intellectual property (IP) is no longer a simple legal instrument; it is

The Valuator’s Teacup: Why Pharma Forecasting Is a High-Stakes Riddle The Fundamental Challenge of Pharmaceutical Valuation The pharmaceutical and biotechnology